Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05474430 · ClinicalTrials.gov registry record
Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
A clinical trial of Carrier State and Respiratory Infections, sponsored by Philip Polgreen.
- Recruiting
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT05474430: Recruiting study of Carrier State and Respiratory Infections, sponsored by Philip Polgreen.
NCT05474430 is a study of Carrier State and Respiratory Infections that is actively recruiting participants, run by Philip Polgreen. The registered enrollment target is 160 participants, below the 1,150-participant average among 3 other Carrier State trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05474430, a study of Carrier State and Respiratory Infections, is actively recruiting participants, sponsored by Philip Polgreen.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19. The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.
Primary Outcome
Comparison of chloride transport values in cystic fibrosis carrier group vs control group via t-test.
Conditions Studied
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2026-07 |
What NCT05474430 shows while recruiting
NCT05474430 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,150-participant average among 3 other Carrier State trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Carrier State appearing as the primary indexed condition, and to 0 interventions.
NCT05474430 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT05474430 about?
NCT05474430 is a clinical study titled "Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity". A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactiv...
What is the current status of trial NCT05474430?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2021-12-20. Estimated completion is 2026-07.
What conditions does trial NCT05474430 study?
This clinical trial studies the following conditions: Carrier State, Respiratory Infections.
Who is sponsoring clinical trial NCT05474430?
This trial is sponsored by Philip Polgreen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05474430 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carrier State
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI